Cumberland Pharmaceuticals Inc. has announced the latest results from its Phase 2 FIGHT DMD trial evaluating ifetroban, an oral therapy for Duchenne muscular dystrophy (DMD) heart disease. These findings, which were presented at the Parent Project Muscular Dystrophy Annual Conference, demonstrate ifetroban's potential to protect the heart and reduce cardiac damage in DMD patients. The trial results, featuring new pharmacokinetic and cardiac biomarker data, indicate potential improvements in heart function and reduction in cardiac damage markers. The complete presentation is available on Cumberland's website.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。